Fed’s Powell opens door to potential rate cuts at Jackson Hole
Geoffrey Craig Porges, Executive Vice President and Chief Financial Officer of Schrodinger, Inc. (NASDAQ:SDGR), recently sold 5,491 shares of the company’s common stock. The shares were sold at a price of $21.76 each, amounting to a total transaction value of $119,484. The sale occurred near current trading levels, with the stock currently valued at $21.08. According to InvestingPro analysis, analysts see significant upside potential, with price targets ranging from $26 to $45.
This sale was carried out as part of a pre-arranged trading plan, specifically to cover withholding tax liabilities incurred upon the vesting of performance-based restricted stock units. These units were initially awarded in August 2022 and vested on March 3, 2025, after the company’s compensation committee certified the achievement of specific performance metrics. With a market capitalization of $1.54 billion and a beta of 1.62, InvestingPro data shows the stock exhibits higher volatility than the broader market.
Additionally, Porges acquired 12,500 restricted stock units and 14,850 performance-based restricted stock units, both at no cost, as part of the company’s equity incentive plans. He also received stock options to purchase 50,000 shares, exercisable at $21.24 per share, with vesting scheduled to begin in March 2026. The company maintains a strong financial position, with InvestingPro analysis showing more cash than debt on its balance sheet and a healthy current ratio of 3.31x. Get access to 6 more exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Schrodinger Inc . reported its fourth-quarter 2024 earnings, which exceeded analysts’ expectations. The company’s earnings per share (EPS) came in at -$0.24, surpassing the forecasted -$0.33. Schrodinger’s revenue for the quarter also beat projections, reaching $88.3 million compared to the anticipated $82.8 million. For the full year, Schrodinger’s total revenue rose to $288 million, up from $217 million in 2023, with software revenue growing by 13.3% year-over-year to $180 million. However, the company faced a decline in drug discovery revenue, which fell to $27 million from $58 million the previous year.
In terms of other developments, Schrodinger announced a significant new drug discovery agreement with Novartis (SIX:NOVN) and expanded collaborations with Otsuka and Lilly. Looking forward, the company anticipates a 10-15% growth in software revenue for 2025 and expects drug discovery revenue to range between $45 million and $50 million. Additionally, the company projects its software gross margin to be between 74% and 75% in the coming year. Meanwhile, Schrodinger’s exposure to US-China trade tensions is minimal, with revenue from China being less than 5%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.